Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,588 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer-Related Condition Clear all
Completed Phase 2 Interventional

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00003008
View directory record Official record
Conditions
Sarcoma
Interventions
indinavir sulfate, nelfinavir mesylate, paclitaxel, ritonavir, saquinavir mesylate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 26, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study

NCT04839588
View directory record Official record
Conditions
Chemotherapy-Related Cognitive Impairment, Healthy
Interventions
Usability study
Other
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
20 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 26, 2026, 5:30 PM EDT
Recruiting Not applicable Interventional

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

NCT07426913
View directory record Official record
Conditions
Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
Interventions
Cardiovascular Health Education and Gaming through Virtual Reality
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

NCT00400946
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Completed No phase listed Observational

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions

NCT02418494
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions
Concept Elicitation, Comprehension Assessment
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 26, 2026, 5:30 PM EDT
Withdrawn Phase 1 Interventional

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

NCT02487459
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
BPX-501, AP1903
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 26, 2026, 5:30 PM EDT
Completed No phase listed Observational

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

NCT02549222
View directory record Official record
Conditions
Transfusion Related Acute Lung Injury
Interventions
Standard of Care
Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
2,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

NCT00006105
View directory record Official record
Conditions
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 26, 2026, 5:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

NCT07030686
View directory record Official record
Conditions
Survivorship, Recurrent, Recurrence, Cancer, Remission
Interventions
Exercise
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Completed No phase listed Observational

MEOI and HRQoL in CLL Patients Treated With BTKis

NCT04938141
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Fountain Valley, California • Redlands, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors

NCT04754529
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Survey Administration, Yoga
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
chemoprotection, complementary or alternative medicine procedure, management of therapy complications
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 26, 2026, 5:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Orca-T, Standard-of-Care
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Not listed Phase 3 Interventional

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

NCT00020865
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cefepime hydrochloride, levofloxacin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

NCT02323867
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplasia
Interventions
CliniMACS α/β T-Cell and CD19+ B-Cell Depleted Peripheral Blood Stem Cell Transplant
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 23 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

NCT00317798
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
anti-thymocyte globulin, sirolimus
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

NCT00004895
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

ADI-PEG in Patients With Metastatic Melanoma

NCT00029900
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
ADI PEG
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 4 Interventional

HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

NCT04474821
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Educational Intervention, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 26, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT03602898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Methotrexate, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Questionnaire Administration, Tacrolimus, Total-Body Irradiation
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 26, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

NCT00041327
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, Etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 26, 2026, 5:30 PM EDT